Ascendis Pharma's TransCon CNP wins positive CHMP opinion for childhood achondroplasia
ASND•The CHMP recommended EU authorization of Ascendis Pharma’s once-weekly TransCon CNP for children aged two or older with achondroplasia and open epiphyses. A final European Commission decision is expected in the fourth quarter of 2026; if authorized, the first EU launch is planned in Germany in the first quarter of 2027 under the YUVIWEL brand.
1. EU authorization recommendation
The CHMP recommended EU authorization of Ascendis Pharma’s once-weekly TransCon CNP for children aged two or older with achondroplasia and open epiphyses. A final European Commission decision is expected in the fourth quarter of 2026, and, if authorized, Ascendis plans to launch the treatment first in Germany in the first quarter of 2027 under the YUVIWEL brand.
